Safety Study on AdCD40L Gene Therapy for Bladder Cancer

NCT00891748 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer

Interventions

GENETIC: AdCD40L

Sponsor

Uppsala University

Collaborators

[object Object]